AHCC characterization for use in different forms and related method
Patent Information
- Application Number
- PCT/TR2023/051894
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-31
- Filing Date
- 2023-12-31
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for producing Active Hexose Correlated Compound (AHCC) are limited in their ability to provide a new form of supplementary nutrition that effectively addresses digestive and immune system issues, particularly for patients with oral nutrition difficulties, and lack efficient regulation of immune-related molecules such as interleukins, interferons, and cytokines.
A method involving the characterization and production of AHCC through a unique process comprising enzymatic digestion, extraction, decompression, condensation, and sterilization of basidiomycetes mycelium, resulting in a composition with at least 50% alpha glucan, which enhances immune function and digestive health by stimulating immune cells and regulating key immune molecules.
The process effectively increases immune response markers, such as dendritic cells and interferon levels, and demonstrates potential antiproliferative effects on cancer cells, providing a potent nutritional supplement that complements traditional treatments for immune and digestive system support.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] AHCC CHARACTERIZATION FOR USE IN DIFFERENT FORMS AND RELATED METHOD
[0002] Technical Field
[0003] The present invention includes the characterization of beta-glucan (P-glucan) and a- glucan, and the active hexose correlated compound (AHCC), which contains mostly polysaccharides, obtained by culturing micelles used in studies that enable the improvement of the digestive and immune systems in the health industry, in forms showing an advantageous effect, alone or in multiple combinations in the body, preferably together with supplementary components. Moreover, the present invention also provides a method of obtaining the said component.
[0004] The State-of-the-Art Technique
[0005] The method (100) characterized and produced by the present invention allows the production of the active hexose correlated compound in a new composition outside the known state of the art.
[0006] Examples of basidiomycetes that can be used for AHCC production include Lentinulla edodes (common name: shiitake mushroom), Agaricus bisporus (common name: button mushroom), Grifola frondosa (common name: maitake), Pholiota nameko (common name: nameko mushroom), Pleurotus ostreatus ( common name: oyster mushroom), Flammulina velutipes (common name: wild enoki mushroom), Ganoderma lucidum (common name: lingzhi), Auricularia auricula (common name: Jew's ear mushroom), Ganoderma applanatum (common name: artist's bracket), Coriolus lucidum (turkey tail), Grifola umbellate (common name: umbrella polypore), Schizophyllum commune (common name: Split Gill) and Volvariella volvacea (common name: straw mushroom). Active hexose correlated compound (AHCC) is a natural compound with a natural structure that positively supports systems of living beings, mostly the immune system and digestive system and has the potential to be used as an immune enhancer. The active hexose correlated compound will be used as AHCC in this invention.
[0007] Active Hexose Correlated Compound (AHCC) is a dietary supplement rich in alphaglucan extracted from the mycelium of Basidiomycota mushrooms such as shiitake (Lentinula edodes).
[0008] Polysaccharides constitute a large part of the composition of AHCC. These include be- ta-glucan (P-glucan) and acetylated a-glucan. Acetylated a-glucan, produced by fermentation and culturing of fungal mycelium, is specific to AHCC. Approximately 20% of AHCC consists of a-glucans.
[0009] Alpha glucans, a compound obtained from natural sugars (sucrose and maltose) through fermentation, are considered prebiotics that support the growth of beneficial organisms. It makes the skin healthier by feeding the beneficial bacteria on the skin.
[0010] Beta glucan stimulates the immune system and activates cells that are effective in immunity. It enables the body of the living being to take precautions against diseases that may occur in its body. It also strengthens the defense mechanism by increasing resistance.
[0011] Figure: 1 Beta Glucan and Alpha Glucan Molecules It is known that AHCC, which can be formed from different forms depending on environmental conditions, acts as an antioxidant. Although research on the health effects of AHCC is quite limited, advocates observe that taking AHCC may provide various health benefits.
[0012] AHCC is a natural compound consisting of alpha-glucan, beta-glucan and polysaccharides obtained from shiitake mushrooms by a defined method via fermentation.
[0013] In the state of the art, AHCC is obtained from the processing of shiitake mushrooms, mainly through fermentation, culturing, separation, drying, condensation and pulverization. Theoretically, it can be produced from quality shiitake mushrooms in many different shapes and conditions with these defined methods.
[0014] During its production, AHCC undergoes a fermentation process that significantly reduces the molecular weight and size of the polysaccharides. Under normal conditions, the weight of polysaccharides is 200,000 Daltons. However, polysaccharides in AHCC are reduced to 5,000 Daltons. By reducing the size of this key ingredient, AHCC has a powerful immune-stimulating effect that ordinary mushrooms and other mushroom supplements do not contain.
[0015] The US2011065629A1 file, which is one of the limited number of studies in the state of the art, defines AHCC as the general name of compounds containing acetylated a- glucan and other polysaccharides obtained by culturing basidiomycete mycelia in large- scale tanks for a long time and removing the culture.
[0016] Studies in the literature show that AHCC has an immune-stimulating function and, accordingly, provides healing potential in some types of conditions. In this regard, it has been the subject of a seriously increasing number of clinical trials and medical studies. It is a compound whose clinical effects have been observed in a number of pharmaceutical and medical studies. With living habits changing day by day, solution methods to heal or eliminate negativity with nutritional supplements are in demand rather than drug-type treatment methods. Accordingly, the number of scientific studies on the known state of the technique has increased considerably in recent years. Chart: 1 Number of AHCC-focused scientific studies by year
[0017] AHCC undergoes a fermentation process that significantly reduces the molecular weight and size of polysaccharides.
[0018] Normally the weight of polysaccharides is 200,000 Daltons; however, polysaccharides in AHCC are reduced to 5,000 Daltons.
[0019] By reducing the size of this key ingredient, AHCC has a powerful immune-stimulating effect that ordinary mushrooms and other mushroom supplements do not contain.
[0020] Study- 1
[0021] According to state-of-the-art studies, AHCC may help boost immunity, according to a small clinical trial in Nutrition and Cancer. For the study, 21 healthy volunteers took either an AHCC supplement or a placebo every day for four weeks. At the end of the study, members of the AHCC group showed a significantly greater increase in the number of dendritic cells, a type of cells involved in the immune response. In the study published by Yin et al., it was observed that AHCC increased the number of CD 4+ and CD 8+ cells, which play an active role in the immune system in bacterial and viral infections, and cancer.
[0022] Table. 1: Yin et al.'s Study on the Effect of AHCC on Immune Cells
[0023] Study-2
[0024] According to studies conducted in another state of the art (Smith, 2019), how IFN-b levels decrease in patients receiving AHCC is clearly shown. A decrease in the level below 20 pg. / ml has been associated with permanent clearance of human papillomavirus (HPV) infection. The significant decrease in IFN-b (green line) at 12 months represents levels in patients receiving unblinded AHCC supplementation. Table 2: Phase II patient interferon-beta (IFN-b) response summary.
[0025] Table 3: Summary of mean percent change in T lymphocytes from baseline in phase II patients.
[0026]
[0027] The change in T lymphocytes is associated with the clearance of human papillomavirus (HPV) infections. (B) Phase II patient's interferon-gamma (IFN-g) response summary. The increase in IFN-g, a type II interferon, is associated with the decrease in IFN-b, a type I interferon, and the resulting clearance of HPV infections.
[0028] Study-3
[0029] In the current state of the art, the study was conducted considering AHCC as supportive treatment in ovarian cancer, aiming to examine the antiproliferative effects of AHCC and to determine the relevant mechanism of action in primary and metastatic ovarian cancer cells.
[0030] It is well known that STAT3 is a critical molecular mediator of biological processes leading to cancer development. In experiments, treatment with pervanadate, a tyrosine phosphatase inhibitor, reversed STAT3 inhibition by AHCC. Gene products regulated by STAT3 were repressed by AHCC. (Signal transducer and activator of transcription 3 is a transcription factor encoded by the STAT3 gene in humans. It is a member of the
[0031] STAT protein family.)
[0032] AHCC, a STAT3 inhibitor, has been found to have potential for use as a therapeutic agent against ovarian cancer. These results indicate that AHCC has an antiproliferative effect on ovarian cancer cell lines through STAT3 phosphorylation; therefore, AHCC has the potential to be complementary to the treatment of ovarian cancer.
[0033] Table 3: Effect of AHCC on STAT3 Molecules Purpose of the Invention
[0034] One purpose of the present invention is to provide a new solution to the problems experienced in the body of the living being by providing a new variety with a new form of a supplementary food containing AHCC to patients who have difficulty in oral nutrition.
[0035] The present invention aims to develop a new solution to digestive and immune system problems by culturing naturally occurring fungi under certain conditions and then subjecting them to various processes.
[0036] One purpose of the present invention is to regulate the production of interleukins, which specifically regulate the development and differentiation of B and T lymphocytes, which have an important role in immunity; interferons, which are proteins syn- thesized by the majority of body cells and act against bacteria, parasites, viruses and tumors; a polypeptide cytokine tumor necrosis factor (TNF), which has important roles in the processes of TNF, natural immunity, cell regulation, cell differentiation and apoptosis, and also ensures the destruction of cancerous cells. Another purpose of the present invention is to allow the increase of the production of interferon, which directly inhibits the replication of viruses and other parasites and increases NK cell activity, tumor necrosis factor (TNF), a group of proteins that help destroy cancer cells by triggering apoptosis (programmed cell death), and cytokines of interleukins (IL-2 and IL- 12), which suppress the production of tumor growth factor (TGF), through AHCC.
[0037] Studies on the immunomodulatory effect of AHCC, a rich nutritional supplement, in animal and human groups are increasing day by day. The method containing the composition and related technique in our current invention finds many solutions listed above and reveals a new nutritional supplement content.
[0038] Description of the invention
[0039] The present invention includes the characterization of beta-glucan (P-glucan) and a- glucan, and the AHCC compound, which contains mostly polysaccharides, obtained by culturing micelles used in the health industry, in forms showing an advantageous effect, alone or in multiple combinations in the body, preferably together with supplementary components, and relevant methods.
[0040] The AHCC production method generally consists of the following five main processes and a total of sixteen processes and, completely different from the known state of the art, contains at least 50% alpha glucan by mass.
[0041] The digestion process is the process of enzymatic reaction of the basidiomycetes species selected to prepare the product with foreign matter and unprocessed ingredients.
[0042] The extraction process is the process of extracting the aroma and the desired active ingredient in the structure of the mushroom.
[0043] Decompression process: It is the process defined as pressure decrease.
[0044] Condensation process: It is the process defined as the transition of a substance from the gas phase to the liquid phase.
[0045] Sterilization process: It is the process of purifying all microorganisms on or in the substance.
[0046]
[0047] * key checkpoint
Claims
CLAIMS1. The present invention includes the characterization of beta-glucan (P-glucan) and a- glucan, and the active hexose correlated compound (AHCC), which contains mostly polysaccharides, obtained by culturing micelles used in studies that enable the improvement of the digestive and immune systems in the health industry, in forms showing an advantageous effect, alone or in multiple combinations in the body, preferably together with supplementary components, and method thereof; its feature is that it contains at least 50% alpha glucan by mass and contains; adding raw contents at key checkpoint, choosing six varieties preferably and adding basidiomycetes mycelia, selection, digestion, extraction, filtering, decompression condensation, sterilization, spray drying, mixing, sieving and inner packaging, outer packaging, label, fi ni shed product / wareh ouse, process steps respectively.
2. Claim 2 has the features of Claim 1, and thanks to its content of at least 50% alpha glucan, which is much higher than that used in the known state of the art, it allows to increase the production of cytokines called interferon, TNF and interleukin.
3. Claim 3 has the features of Claim 1 or Claim 2; The process is operated in a class 100,000 clean room and all equipment used during the process is preferably stainless steel.
4. Claim 4 is a method of preparing a composition according to claim 1, wherein the key control point is included in the first step, the raw ingredients step.
Citation Information
Patent Citations
Beta-glucan-containing fat compositions and novel microorganism producing beta-glucan
US20050255126A1
Enteral nutrient
US20110065629A1
Glycan therapeutics and methods of treatment
WO2016172657A2
